Cell therapy for returning lymphoma study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study collects data from adults with lymphoma that has come back or not improved after treatment, who have received or are receiving special cell therapies. The goal is to learn more about how these treatments work in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of B-cell lymphoma (like DLBCL, follicular, mantle cell, or others) or T-cell lymphoma that has come back or not responded to standard treatment
- You have had or are currently having a cell therapy, such as CAR-T cells, TIL therapy, or other immune cell treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This clinical trial tests a new cell therapy, CT1194D, for people whose B-cell lymphoma (a type of blood cancer) or B-cell acute lymphoblastic leukemia has come back or is not responding to standard treatments. The goal is to see if this therapy can help shrink tumors or improve blood cell counts.
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
Hear when a new Lymphoma, Non-Hodgkin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.